RECRUITING

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this clinical trial is to evaluate the safety and tolerability of TNM005 following a single dose by intramuscular (IM) administration in healthy adult subjects The main questions it aims to answer are:1. safety profile；2. PK properties 3. PD properties

Official Title

A Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNM005 and to Characterize the Pharmacodynamics of TNM005 and VARIZIG in Healthy Adult Volunteers

Quick Facts

Study Start:2023-09-12

Study Completion:2024-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06068608

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* 1) Signed and dated written informed consent; * 2) Are willing and able to comply with scheduled visits, blood sampling, laboratory tests, and other study procedures; * 3) Healthy males or females, 18-55 years of age (both inclusive); * 4) Body mass index (BMI) within 18.5-31.0 kg/m2 (both inclusive) and body weight ≥50.0 kg for males and ≥45.0 kg for females; * 5) Have no clinically significant abnormality on physical examination, vital signs, 12-lead ECG, and clinical laboratory tests as determined by the Investigator; * 6) Females must be either surgically sterile or under post-menopausal status at Screening or agree to use a highly effective method of contraception from screening until 120 days after IMP dosing. In addition, males who are sexually active and partners of women of childbearing potential must agree to use effective contraception from screening until 120 days after drug administration.	* 1) History or evidence of any other acute or chronic disease that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the drug or compromise the safety of the subject; * 2) History of surgery (except minor outpatient surgery) within three months prior to screening or planned surgery during the study; * 3) History of receiving monoclonal antibody, immunoglobulin, or blood products within six months prior to dosing; * 4) Receipt of systemic immunosuppressive medications; * 5) Exposure to any live attenuated vaccine within four weeks prior to drug administration; * 6) History of receiving vaccine(s) against zoster; * 7) Use of any other drug, including over-the-counter medications, and herbs, within 14 days prior to the drug administration or five half-lives of the drug, whichever is longer, except for contraceptive medication in women of childbearing potential (WOCBP), or concomitant medications that are considered necessary for the subject's welfare and unlikely to interfere with the study; * 8) Donated blood \>400 mL or significant blood loss equivalent to 400 mL within one month before Screening; or plasma donation within 14 days before Screening; or any plan of blood or blood product donation during the study; * 9) Positive test at a screening of any of the following: hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody; * 10) Known or suspected history of drug abuse within the past five years or with a positive urine drug test at Screening or on Day -1; * 11) History of significant alcohol abuse within six months prior to screening or any indication of regular use of more than 14 units of alcohol per week or taking a product containing alcohol two days prior to dosing, or having a positive alcohol breath test on Day -1; * 12) Use of ≥five cigarettes or equivalent nicotine-containing product per day on average over three months prior to Screening; or unwilling to refrain from nicotine products during study participation; * 13) History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein; * 14) History of allergic or anaphylactic reaction to blood products (only for VARIZIG cohort); * 15) IgA deficient subjects at risk for hypersensitivity reaction (only for VARIZIG cohort); * 16) Subjects at high risk for thrombotic events, including those with a history of venous or arterial thrombosis, atherosclerosis, or multiple cardiovascular risk factors (only for VARIZIG cohort); * 17) Participation in any other clinical studies with chemical or biological drugs or devices within four weeks or five times the half-life of the specific drug/biologics (whichever is longer) before drug administration; * 18) Nursing mothers or pregnant women; * 19) Subjects considered unsuitable for participating in the study in the opinion of the Investigator.

Inclusion Criteria

Exclusion Criteria

* 1) Signed and dated written informed consent;
* 2) Are willing and able to comply with scheduled visits, blood sampling, laboratory tests, and other study procedures;
* 3) Healthy males or females, 18-55 years of age (both inclusive);
* 4) Body mass index (BMI) within 18.5-31.0 kg/m2 (both inclusive) and body weight ≥50.0 kg for males and ≥45.0 kg for females;
* 5) Have no clinically significant abnormality on physical examination, vital signs, 12-lead ECG, and clinical laboratory tests as determined by the Investigator;
* 6) Females must be either surgically sterile or under post-menopausal status at Screening or agree to use a highly effective method of contraception from screening until 120 days after IMP dosing. In addition, males who are sexually active and partners of women of childbearing potential must agree to use effective contraception from screening until 120 days after drug administration.

* 1) History or evidence of any other acute or chronic disease that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the drug or compromise the safety of the subject;
* 2) History of surgery (except minor outpatient surgery) within three months prior to screening or planned surgery during the study;
* 3) History of receiving monoclonal antibody, immunoglobulin, or blood products within six months prior to dosing;
* 4) Receipt of systemic immunosuppressive medications;
* 5) Exposure to any live attenuated vaccine within four weeks prior to drug administration;
* 6) History of receiving vaccine(s) against zoster;
* 7) Use of any other drug, including over-the-counter medications, and herbs, within 14 days prior to the drug administration or five half-lives of the drug, whichever is longer, except for contraceptive medication in women of childbearing potential (WOCBP), or concomitant medications that are considered necessary for the subject's welfare and unlikely to interfere with the study;
* 8) Donated blood \>400 mL or significant blood loss equivalent to 400 mL within one month before Screening; or plasma donation within 14 days before Screening; or any plan of blood or blood product donation during the study;
* 9) Positive test at a screening of any of the following: hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody;
* 10) Known or suspected history of drug abuse within the past five years or with a positive urine drug test at Screening or on Day -1;
* 11) History of significant alcohol abuse within six months prior to screening or any indication of regular use of more than 14 units of alcohol per week or taking a product containing alcohol two days prior to dosing, or having a positive alcohol breath test on Day -1;
* 12) Use of ≥five cigarettes or equivalent nicotine-containing product per day on average over three months prior to Screening; or unwilling to refrain from nicotine products during study participation;
* 13) History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein;
* 14) History of allergic or anaphylactic reaction to blood products (only for VARIZIG cohort);
* 15) IgA deficient subjects at risk for hypersensitivity reaction (only for VARIZIG cohort);
* 16) Subjects at high risk for thrombotic events, including those with a history of venous or arterial thrombosis, atherosclerosis, or multiple cardiovascular risk factors (only for VARIZIG cohort);
* 17) Participation in any other clinical studies with chemical or biological drugs or devices within four weeks or five times the half-life of the specific drug/biologics (whichever is longer) before drug administration;
* 18) Nursing mothers or pregnant women;
* 19) Subjects considered unsuitable for participating in the study in the opinion of the Investigator.

Contacts and Locations

Study Contact

Ying Wang

CONTACT

+86 0756 7263999

emma.wang@trinomab.com

Miaoyan Chen

CONTACT

+86 0756 7263999

chenmiaoyan@trinomab.com

Principal Investigator

Ahad Sabet, MD

PRINCIPAL_INVESTIGATOR

ICON plc

Study Locations (Sites)

ICON, plc

Salt Lake City, Utah, 84124

United States

Collaborators and Investigators

Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.

Ahad Sabet, MD, PRINCIPAL_INVESTIGATOR, ICON plc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-12

Study Completion Date2024-12-31

Study Record Updates

Study Start Date2023-09-12

Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

Varicella